EXBIO Antibodies Product Data Sheet

1B-453-C025

Monoclonal Antibody to CD105
Biotin conjugated (0.025 mg)

Clone: MEM-229
Isotype: Mouse IgG2a
Specificity: The antibody MEM-229 recognizes CD105 (Endoglin), a 90 kDa type I integral membrane homodimer glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow and erythroid precursors in fetal and adult bone marrow; it is also present on syncytiotrophoblast on placenta throughout pregnancy.
Regulatory Status: RUO
Immunogen: Recombinant Vaccinia virus containing the human CD105 (L-isoform) cDNA.
Species Reactivity: Human, Porcine
Preparation: The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.
Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability: Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Usage: Biotinylated antibody is designed for indirect immunofluorescence analysis by Flow Cytometry.
Expiration: See vial label
Lot Number: See vial label
Background: CD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFbetaR-2 as a receptor for TGFbeta-1 and TGFbeta-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonises the inhibitory effects of TGFbeta-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.
References:
*Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke. 2003 Oct;34(10):2483-8.
*Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003 Jul 1;116(Pt 13):2677-85.
*Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, Bernabeu C, Kumar S: CD105 inhibits transforming growth factor-beta-Smad3 signalling. Anticancer Res. 2004 May-Jun;24(3a):1337-45.
*Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res. 2005 May-Jun;25(3B):1851-64.
*Piao M, Tokunaga O: Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb. 2006 Apr;13(2):82-9.
*Plánka L, Necas A, Srnec R, Rauser P, Starý D, Jancár J, Amler E, Filová E, Hlucilová J, Kren L, Gál P: Use of allogenic stem cells for the prevention of bone bridge formation in miniature pigs. Physiol Res. 2009;58(6):885-93.

 


For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 42 Vestec u Prahy | Czech Republic

Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz